The patent eligibility of human embryonic stem cell technology in Europe - What happened after Brüstle?
Aktivitet: Tale eller præsentation - typer › Foredrag og mundtlige bidrag
Timo Minssen - Foredragsholder
- JUR Forskningscenterområdet
- JUR Center for Informations- og innovationsret
On 18 October, 2011 the CJEU rendered its decision in Brüstle v Greenpeace. Interpreting key -provisions of the EU Biotech Directive, the Court held that a process which involves removal of a stem cell from a human embryo at the blastocyst stage, entailing the destruction of that embryo, cannot be patented. This presentation will analyse the context, outcome & implications of this seminal judgment, which complements the EPO’s WARF decision and which has now also been reflected in the EPO’s new examination guidelines (June 2012), as well as in subsequent decisions by i.a. the German BGH, the UK courts and the EPO.
12 aug. 2013
|Titel||Pharmaceutical Law & Policy- Hot topics shaping the future of the pharma industry|
|Forkortet titel||CSU 2013|
|Dato||12/08/2013 → 16/08/2013|